<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04581642</url>
  </required_header>
  <id_info>
    <org_study_id>CLI-01-1-09</org_study_id>
    <nct_id>NCT04581642</nct_id>
  </id_info>
  <brief_title>Nociception-Level (NOL) for the Assessment of Pain in Patient Unable to Self-Report</brief_title>
  <acronym>MoNOLog</acronym>
  <official_title>Nociception-Level (NOL) for the Assessment of Pain in Patient Unable to Self-Report: An Exploratory, Prospective, Unblinded, Single-center Study- The MoNOLog Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medasense Biometrics Ltd</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medasense Biometrics Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study we aimed to investigate the performance and effectiveness of NOL and/or NOLedge&#xD;
      as a tool for pain assessment in geriatric and critical ill non communicating patients.&#xD;
&#xD;
      Our hypothesis was that NOL and the NOLedge may have good correlation with the health-care&#xD;
      professional assessment PAINAD, BPS values, even with the use of the drugs affecting&#xD;
      autonomic nervous system.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy outcome</measure>
    <time_frame>5 months</time_frame>
    <description>To identify what information is currently elicited and used by clinicians when detecting and managing pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy outcome</measure>
    <time_frame>5 months</time_frame>
    <description>To assess the feasibility of the current NOL algorithm (PMD200 vs. NOLedge) for pain management in the study population.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy outcome</measure>
    <time_frame>5 months</time_frame>
    <description>To collect data to improve the performance of the NOL algorithm in the study population</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy outcome</measure>
    <time_frame>10 months</time_frame>
    <description>The ability of the NOL index to discriminate between periods of painful and non-painful periods</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy outcome</measure>
    <time_frame>10 months</time_frame>
    <description>NOL-index performance to detect pain in comparison to PAINAD, BPS pain scores</description>
  </secondary_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Pain</condition>
  <condition>Opioid Use</condition>
  <condition>Dementia</condition>
  <condition>Unconscious</condition>
  <condition>Ventilator Lung</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PMD200</intervention_name>
    <description>The NOL technology is comprised of a console and designated finger probe with 4 sensors. The Sensors are Photoplethysmography (PPG) Galvanic Skin Response (GSR), Accelerometer (ACC) and Thermistor (TMP)</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a clinical syndrome due to disease of a progressive nature, which leads to&#xD;
        disturbances in multiple higher cortical functions, including memory, thinking,&#xD;
        orientation, comprehension, calculation, learning capacity, language and judgment;&#xD;
&#xD;
          1. Older adults with advanced dementia;&#xD;
&#xD;
          2. Critically ill/unconscious patients;&#xD;
&#xD;
          3. Patients at the end of life stage.&#xD;
&#xD;
          4. Ventilated patients.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female, Age &gt; 18 years old.&#xD;
&#xD;
          -  Spontaneously breathing or mechanically ventilated&#xD;
&#xD;
          -  Any patient who is unable to express his/her own level of personal pain by using&#xD;
             visual scales according to the hospital standard&#xD;
&#xD;
          -  Written informed consent provided by the participant (if they have capacity) or&#xD;
             guardian (if they do not have capacity) or a written proxy informed consent from a&#xD;
             legally authorized representative empowered to make health-related decisions for the&#xD;
             potential study participant.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A patient whose staff or research team believes that his or her participation in the&#xD;
             research will cause suffering to the patient.&#xD;
&#xD;
          -  Unstable condition preventing planned routine procedures of care, and conditions&#xD;
             precluding the use of PMD-200: absence of sinus cardiac rhythm.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adi Sasson, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>DOROT, Netanya Geriatric Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mira Sofer</last_name>
    <phone>+972-3-5183878</phone>
    <email>mira@medasense.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arik Tzour</last_name>
    <phone>+972-3-5183878</phone>
    <email>arik@medasense.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dorot Netanya Gariatric Medical Center</name>
      <address>
        <city>Netanya</city>
        <zip>42420</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roi Sasson, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 3, 2020</study_first_submitted>
  <study_first_submitted_qc>October 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2020</study_first_posted>
  <last_update_submitted>May 2, 2021</last_update_submitted>
  <last_update_submitted_qc>May 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Unconsciousness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

